Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
IPLEX is a subcutaneous injectable small molecule approved by BLA in December 2005 for an undisclosed indication. The specific mechanism of action and therapeutic area are not documented in available data. Patient population details cannot be determined without indication information.
As a mature product approaching loss of exclusivity with low competitive pressure (30%), the brand team is likely in maintenance or transition mode with stable but not expanding headcount.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Trial to Evaluate the Safety and Immunogenicity of a Modified Vaccinia Ankara (MVA)-Based Anti-Cytomegalovirus (CMV) Vaccine (Triplex®)
Differential Target Multiplexed Spinal Cord Stimulation (DTM-SCS®) Real World Outcomes
Confirmatory Clinical Study of Oxiplex
Study of Octaplex, a Four-factor Prothrombin Complex Concentrate (4F-PCC) and Beriplex® P/N (Kcentra) for the Reversal of Vitamin K Antagonist (VKA) Induced Anticoagulation in Patients Needing Urgent Surgery With Significant Bleeding Risk.
A Novel Multiplex ELISA Assay for Evaluating Patients With Gross Hematuria for Bladder Cancer
Worked on IPLEX at Insmed? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Insmed is hiring 1 role related to this product
Zero linked job postings indicate minimal active hiring for this product, reflecting its mature, non-growth stage. Roles on IPLEX are typically focused on market maintenance, formulary management, and defending market share against generics rather than expansion or innovation.